SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-1.1
Date Filed: 2025-08-27
Accession Number: 0001213900-25-081175
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex1-1_synergy.htm

Chunk 10 of 27
Word Count: 1208
Character Count: 7680

Document Content:

to make the statements therein, in light of the circumstances then existing, not misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its counsel or the Representative or counsel to the Underwriters to amend the Registration Statement or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package ) to comply with the Securities Act, the Company will promptly notify the Representative, allow the Representative the opportunity to provide reasonable comments on such amendment, prospectus supplement or document, and will amend the Registration Statement or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance.

(B) If at any time
during the Prospectus Delivery Period there occurred or occurs an event or development the result of which such Issuer Free Writing Prospectus
conflicted or would conflict with the information contained in the Registration Statement or any Prospectus or included or would include,
when taken together with the Time of Sale Disclosure Package, an untrue statement of a material fact or omitted or would omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances prevailing at that subsequent time, not
misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer
Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

(v) The Company shall
take or cause to be taken all necessary action to qualify the Shares for sale under the securities laws of such jurisdictions as the Representative
reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Shares, except that
the Company shall not be required in connection therewith to qualify as a foreign corporation or as a dealer in securities in any jurisdiction
in which it is not so qualified, to execute a general consent to service of process in any state or to subject itself to taxation in respect
of doing business in any jurisdiction in which it is not otherwise subject.

(vi) The Company will
furnish to the Representative and counsel to the Underwriters copies of the Registration Statement, each Prospectus, any Issuer Free Writing
Prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as the Representative
may from time to time reasonably request.

(vii) The Company
will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end
of the Company’s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall
satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.

(viii) The Company,
whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid (A)
all expenses (including transfer taxes allocated to the respective transferees) incurred in connection with the delivery to the Underwriters
of the Shares (including all fees and expenses of the registrar and transfer agent of the Shares and the registrar and transfer agent
of the Representative Warrants (if other than the Company), and the cost of preparing and printing stock certificates and warrant certificates,
(B) all reasonable expenses and reasonable fees (including, without limitation, fees and expenses of the Company’s counsel) in connection
with the preparation, printing, filing, delivery, and shipping of the Registration Statement (including the consolidated financial statements
therein and all amendments, schedules, and exhibits thereto), the Shares, the Time of Sale Disclosure Package, any Prospectus, the Final
Prospectus, any Issuer Free Writing Prospectus and any amendment thereof or supplement thereto, (C) all reasonable and documented filing
fees and reasonable fees and disbursements of the Underwriter’s counsel incurred in connection with the qualification, if required,
of the Shares for offering and sale by the Underwriters or by dealers under the securities or blue sky laws of the states and other jurisdictions
that the Representative shall designate, (D) the reasonable and documented filing fees and reasonable and documented fees and disbursements
of counsel to the Underwriter incident to any required review and approval by FINRA, of the terms of the sale of the Shares, (E) listing
fees, if any, and (F) all other costs and expenses incident to the performance of its obligations hereunder that are not otherwise specifically
provided for herein. At and contingent upon Closing, the Company will reimburse the Representative for the Underwriters’ reasonable
out-of-pocket expenses, including legal fees, disbursements, roadshow expenses, cost of background checks, and other out of pocket expenses
in connection with the purchase and sale of the Securities contemplated hereby up to an aggregate of $75,000 (including amounts payable
pursuant to clauses (C) and (D) above which are also contingent upon Closing). Moreover the Company agrees to reimburse the Representative
for closing costs in connection with the Representative’s efforts to arrange for its clearing agent to provide the funds to facilitate
settlement of the offering and sale of the Shares on a delivery versus payment basis, including without limitation, the reimbursement
of the out-of-pocket costs of any escrow agent or clearing agent, as applicable, which closing costs shall not exceed $14,900 in the aggregate.

(ix) The Company intends
to apply the net proceeds from the sale of the Shares to be sold by it hereunder for the purposes set forth in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus under the heading “Use of Proceeds”.

(x) The Company has
not taken and will not take, directly or indirectly, during the Prospectus Delivery Period, any action designed to or which might reasonably
be expected to cause or result in, or that has constituted, the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Shares. For the sake of clarity, actions by the Representative or persons acting on its behalf
will not constitute direct or indirect action by the Company for the purposes of this clause.

(xi) The Company represents
and agrees that, unless it obtains the prior written consent of the Representative, it has not made and will not make any offer relating
to the Shares that would constitute an Issuer Free Writing Prospectus; provided that the prior written consent of the parties hereto shall
be deemed to have been given in respect of the free writing prospectuses included in Schedule III. Any such free writing prospectus consented
to by the Company and the Representative is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company
represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,”
as defined in Rule 433, and has complied or will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus,
including timely Commission filing where required, legending and record-keeping.